SCHEMBL4413089

SCHEMBL4413089

CCC[C@@H]1COC(C)(C)O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.46
ALDH1A1 P00352 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM3 P20309 1/20 0.35
TMEM97 Q5BJF2 2/20 0.34
SIGMAR1 Q99720 2/20 0.34
HSP90AA1 P07900 1/20 0.34
CYP3A4 P08684 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
PKM P14618 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
MAPK1 P28482 1/20 0.32
CASP1 P29466 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8330854 1.00 CA2 (0.46) CA2ALDH1A1NPSR1CHRM2CHRM4
SCHEMBL10304985 1.00 CA2 (0.46) CA2ALDH1A1NPSR1CHRM2CHRM4
SCHEMBL18817541 0.88 CA2 (0.50) CA2ALDH1A1NPSR1CHRM2CHRM4
SCHEMBL7154999 0.88 CA2 (0.50) CA2ALDH1A1NPSR1CHRM2CHRM4
SCHEMBL13637952 0.87 ALDH1A1 (0.43) CA2ALDH1A1NPSR1CHRM2CHRM4
SCHEMBL10065754 0.87 ALDH1A1 (0.43) CA2ALDH1A1NPSR1CHRM2CHRM4
SCHEMBL10972837 0.85 ALDH1A1 (0.52) CA2ALDH1A1NPSR1CHRM2CHRM4
SCHEMBL12059431 0.85 ALDH1A1 (0.52) CA2ALDH1A1NPSR1CHRM2CHRM4
SCHEMBL13130046 0.84 CA2 (0.47) CA2ALDH1A1NPSR1CHRM2CHRM4
SCHEMBL10974424 0.84 ALDH1A1 (0.55) CA2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180141889-A1 METHODS OF SYNTHESIZING A PROSTACYCLIN ANALOG CAYMAN CHEMICAL COMPANY INCORPORATED (US) 2018-05-24 US disclosed
US-20180118656-A1 AMINE SALTS OF A PROSTACYCLIN ANALOG CAYMAN CHEMICAL COMPANY INCORPORATED (US) 2018-05-03 US disclosed
US-9908834-B2 Methods of synthesizing a prostacyclin analog CAYMAN CHEMICAL COMPANY INCORPORATED (US) 2018-03-06 US disclosed
US-9890104-B2 Amine salts of a prostacyclin analog CAYMAN CHEMICAL COMPANY INCORPORATED (US) 2018-02-13 US disclosed
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-21 US disclosed
US-20170297995-A1 METHODS OF SYNTHESIZING A PROSTACYCLIN ANALOG CAYMAM CHEMICAL COMPANY INCORPORATED (US) 2017-10-19 US disclosed
WO-2017064701-A1 METHODS FOR TOTAL SYNTHESIS OF RESOLVIN E1 SALZMAN LOVELACE INVESTMENTS, LTD. (IL) 2017-04-20 WO disclosed
US-20160289158-A1 Amine Salts of a Prostacyclin Analog CAYMAN CHEMICAL COMPANY INCORPORATED (US) 2016-10-06 US disclosed
US-20150315114-A1 Methods of Synthesizing a Prostacyclin Analog CAYMAN CHEMICAL COMPANY INCORPORATED 2015-11-05 US disclosed
US-20120172321-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
US-8178689-B2 Tricyclic compounds HOFFMAN-LA ROCHE INC. (US) 2012-05-15 US disclosed
US-20110313002-A1 TRICYCLIC COMPOUNDS SARABU RAMAKANTH (US) 2011-12-22 US disclosed
US-8071766-B2 HSP90 inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-06 US disclosed
US-20110053873-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-03 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
EP-2057165-A1 ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES INDUSTRIAL RESEARCH LIMITED (NZ) 2009-05-13 EP disclosed
WO-2008030119-A1 ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES INDUSTRIAL RESEARCH LIMITED (NZ) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160289158-A1 Amine Salts of a Prostacyclin Analog PTGIS, PTGIR, PTGER1 CA2 1199/4885ALDH1A1 519/4885NPSR1 85/4885
US-20090305998-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CA2 4094/4885ALDH1A1 1601/4885NPSR1 4385/4885
US-20150315114-A1 Methods of Synthesizing a Prostacyclin Analog PTGIS, CYP11B2, CYP11B1 CA2 406/4885ALDH1A1 257/4885NPSR1 2036/4885
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 CA2 3437/4885ALDH1A1 1526/4885NPSR1 2228/4885
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 CA2 2535/4885ALDH1A1 1129/4885NPSR1 3628/4885
US-20180141889-A1 METHODS OF SYNTHESIZING A PROSTACYCLIN ANALOG PTGIS, CYP11B1, CYP11B2 CA2 465/4885ALDH1A1 278/4885NPSR1 2209/4885
US-20180118656-A1 AMINE SALTS OF A PROSTACYCLIN ANALOG PTGIS, PTGIR, PTGER1 CA2 1199/4885ALDH1A1 519/4885NPSR1 85/4885
US-20110053873-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CA2 4141/4885ALDH1A1 1554/4885NPSR1 4375/4885
US-20170297995-A1 METHODS OF SYNTHESIZING A PROSTACYCLIN ANALOG PTGIS, CYP11B2, CYP11B1 CA2 406/4885ALDH1A1 257/4885NPSR1 2036/4885
US-20120172321-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CA2 4094/4885ALDH1A1 1601/4885NPSR1 4385/4885
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 CA2 3515/4885ALDH1A1 1246/4885NPSR1 39/4885
US-20110313002-A1 TRICYCLIC COMPOUNDS GPR119, PC, GOT2 CA2 2100/4885ALDH1A1 545/4885NPSR1 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.